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Calcium kinetics and the long-term effects of lowering dialysate calcium
concentration. The optimal dialysate calcium (Ca) content for hemodi-
alysis has been classically fixed at 1.75 m. However, this dialysate Ca
concentration (dCa) with its positive intradialytic Ca balance combined
with the use of CaCO3 as a phosphate binder may result in hypercal-
cemia. To prevent or treat hypercalcemia, a decrease in dCa has been
proposed. In the present study both the acute and the long-term effects
of lowering dCa were assessed. Additionally, given the results obtained
after one year with low dCa the effectiveness of i.v. la vitamin D3 in
lowering PTH serum levels in two groups of patients dialyzed with
different dCa was also studied. (a) Ca kinetics during hemodialysis (HD)
and on line hemodiafiltration (HDF) were studied in a group of nine
stable patients who were sequentially treated with 1.75, 1.5 and 1.25
mM dCa. Dialysate was the same but for the dCa which was lowered
stepwise. Na, K, tCa, ionized Ca (iCa), proteins, phosphate and pH
were measured from blood inlet and outlet and dialysate outlet at the
start, one hour, two hours and after the treatments. At the same time
weight, blood pressure and heart rate were recorded. The sieving of iCa
was significantly different in HDF versus HD (F = 6.73; P < 0.01);
intravenous infusion of 18 liters of filtered ultrapure dialysate compen-
sated the Ca loss due to the convective component of HDF, as iCa was
similar at the blood inlet in HD and HDF in the three dCa tested (F =
2.59; NS). Intradialytic iCa kinetics measured in the blood inlet were
significantly different with different dCa (P < 0.001 for 1,75 mM vs. 1.5
mm and P < 0.001 for 1.5 m vs. 1.25 mM). A significant increase in
post-dialysis iCa was observed with dCa of 1.75 and 1.5 while no
modification was observed with 1.25 mM dCa. (b) Regarding long-term
effects of lowering dCa, seven of the nine patients acutely studied were
followed for a one year period after changing from dCa = 1.5 to dCa =
1.25 ms. A control group of six patients was maintained with dCa = 1.5
for the same period of time and with the same treatment schedule but
for dCa. Total Ca, phosphate and alkaline phosphatase were assessed
monthly, and phosphate binders and oral vitamin D derivative doses
were adapted accordingly. Intact PTH was determined quarterly.
CaCO3 oral intake was more than doubled in the low dCa group. Total
Ca, phosphate and ALP were similar in both groups over the assessed
year. However, a significant increase in PTH was observed after one
year treatment with 1.25 mri dCa (94 40 vs. 296 99 pg/ml; P < 0.05)
which was not observed in the dCa = 1.5 m control group (92 24 vs.
113 24 pg/mI; NS). (c) For the effects of high-dose i.v. 1 a vitamin D3
on PTH serum levels, six of the patients maintained with dCa = 1.25
mM for one year tolerated the treatment with la vitamin D3. A control
group of six patients dialyzed with dCa = 1.5 m and with comparable
PTH levels was submitted to identical treatment and follow-up. High
dose i.v. Ia vitamin D3 resulted in a similar iPTH reduction (72 and
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75%; P < 0.0313) in both groups within four months of treatment. This
study shows that low dCa can be used both in HD and HDF with no
associated clinical intolerance. However, the increase in oral Ca intake
was not sufficient to prevent the stimulation of PTH secretion observed
with dCa = 1.25 m. Complementary treatment with high doses of
vitamin D derivatives reverses PTH increase both in 1.5 and 1.25 mi
dCa treated patients.
Osteoarticular disease is a major concern in hemodialysis
patients. The known pathogenic factors for bone disease in this
population are multiple and interrelated: hyperparathyroidism,
aluminum toxicity, osteomalacia and the more recently added
dialysis-associated amyloidosis [1]. While the pathogenesis of
the latter is currently under study, important progress has been
achieved in the treatment and prevention of the other three in
the last few years. Serum phosphate control can be obtained
without the use of Al-containing phosphate binders and new
vitamin D derivatives with different efficacy, administration
techniques and side effects are available or under pre-clinical
experimentation [2—4]. However, the new trends in the treat-
ment of hyperparathyroidism generate different problems which
require modifications of the classical approach to dialysis
therapy [5]. One of the limiting factors in the use of high doses
of CaCO3 in phosphate control is that of hypercalcemia. To
avoid hypercalcemia a reduction in the dialysate Ca content
(dCa) has been proposed [6].
In the present study we wanted to compare the intrasession
Ca kinetics in hemodialysis and our previously-described on-
line hemodiafiltration system [7] using three different dCa
concentrations. Besides the acute clinical consequences sec-
ondary to the lowering of dCa, long-term results were examined
in a 12 month prospective protocol. Our results show that
lowering dCa to 1.25 mri is safe from the point of view of
potential hypocalcemia, intradialytic events and blood pressure
control. However, a 2.8-fold increase in oral calcium intake
with subsequent normalization of serum Ca levels was not
sufficient to prevent stimulation of PTH secretion, as compared
to a control group maintained with 1.5 mrt dCa. High doses of
i.v. liz vitamin D3 can be given to both 1.5 and 1.25 ma't dCa
treated patients with identical good results in decreasing PTH.
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Methods
Calcium kinetics and intradialytic studies
Patients. Seven men and two women with stable end-stable
renal failure gave their consent to participate in the trial. Their
mean age was 53.2 4 years old (range: 31 to 72) and they had
been on kidney replacement therapy for 5.8 1.7 years. Their
kidney diseases included chronic glomerulonephritis (3),
chronic urinary tract infection (2), Henoch-Schonlein syndrome
(1), Wegener's disease (1), and undetermined (2). One patient
was receiving labetalol as the antihypertensive treatment.
Kidney replacement techniques. This group of patients was
routinely treated with post-dilutional hemodiafiltration (HDF)
for three hours each, three times weekly with A-2008-C Frese-
nius machines and HF8O polysulfone membranes (Fresenius
AG, Bad Homburg, Germany). Blood flow was maintained
between 350 and 380 mllmin. Sterile, bicarbonate buffered
infusate was produced by on-line filtration of ultrapure dialysate
as previously described [7]. Ion contents were: Na 139 mM, K
1.5 m, Mg 0.5 mM, Cl 108 mM, HC03 36 m, and the Ca
content was decreased from 1.75 to 1.5 and 1.25 mM. A total
convective volume removal of 18 to 20 liters was used with 500
ml/min dialysate flow. Weight was monitored with Gambro
weigh beds (Gambro, Lund Sweden), and blood pressure was
measured with a Dinamap 8103 (Critikon, Creteil, France).
Dialysis dose was controlled by urea kinetics measurements
every month according to Farrel's method [81 as detailed
elsewhere [9]; a Kr/V > 1.4 with a PCR> 1 was sought.
Simple hemodialysis (HD) without the convective part of
HDF but using the same dialysis parameters as above was
performed in all patients, with the three dCa concentrations to
analyze the differences between HD and HDF.
Parameters. iCa, Na and K were measured with specific
electrodes (Fresenius EH-F lonometer; the intra-assay and
interassay variability was <0.1% and <1%, respectively) in
blood taken from the arterial and venous sides of the blood
circuit, as well as in the dialysate taken from the outlet of the
dialyzer, at the start, one hour, two hours, and at the end of the
three-hour dialysis session. Total Ca (tCa) was manually deter-
mined by fluorometric measurement of calcein reaction with an
intra-assay and interassay variability <1%. At the same time
phosphate, total protein and bicarbonate were measured with a
Kone autoanalyzer (KONE mc, Finland).
Protocol of calcium kinetics assessment. The patients were
maintained on 1.75 dCa for more than three months, then Ca
kinetics were assessed in three consecutive sessions (twice
using HDF and a last one with isolated HD). Urea kinetic
assessment was performed the consecutive week and the dCa
changed to 1.5 m the week after, with assessment of Ca
kinetics in the same way (3 consecutive sessions: 2 HDF and 1
isolated HD) 12 weeks after decreasing dCa to 1.5 mM. Identical
assessment was carried out when the patients were changed
from 1.5 to 1.25 mrvi dCa.
Blood pressure and dialysis tolerance. Intradialytic blood
pressure, pulse and weight were recorded before, one hour, two
hours, and at the end of the dialysis session. Intrasession events
were recorded during a one month period while the patient was
treated with the three different dCa concentrations. The results
are expressed as events per 100 dialysis sessions.
Long-term effects of using 1.25 m'i dCa
Patients. One patient was transplanted and another was
transferred to another center shortly after the acute study of the
1.25 mri dCa. The long-term effects of lowering the dCa from
1.5 to 1.25 m were therefore assessed over a one year period
in the remaining seven patients as well as in a control group of
six patients maintained with 1.5 mri dCa throughout the study.
Biological parameters. Ca, phosphate and ALP were as-
sessed pre-dialysis monthly. Osteocalcin and intact parathyroid
hormone (iPTH) were assessed quarterly by RIA (Incstar Co,
Stillwater, Minnesota, USA and Nichols Institute, San Juan
Capistrano, California, USA). The variability for these tests
was 3.4% and 5.6% intra- and interassay, respectively. Phos-
phate binders and oral vitamin D derivative doses were adapted
to maintain tCa in the higher zone of the normal range (2.5 to 2.7
mM) and serum phosphate lower than 1.7 mM.
Blood pressure. Interdialytic systolic and diastolic blood
pressures as well as heart rate were monitored for 24 hours with
a SpaceLabs 90207-31 blood pressure monitor (SpaceLabs Inc.,
Redmond, Washington, USA) during the use of 1.5 and 1.25 mM
dCa in the study group. There was more than 35 readings per
record. The mean of the one day record was used as the blood
pressure for a given patient and used for analysis.
High dose 1 a(OH) vitamin D3
Patients. The seven patients maintained with 1.25 dCa for
more than one year, and a control group (also N = 7) with
equivalent PTH serum levels and maintained with 1.5 dCa
throughout the study were included in the protocol. Oral
1 a(OH) vitamin D3 was stopped and replaced by i.v. 1 a(OH)
vitamin D3. One patient in each group did not tolerate i.v.
la(OH) vitamin D3, and the analysis was performed in the
remaining 12 patients separated into two groups according to
dCa concentration (6 patients treated with 1.5 and 6 treated with
1.25 mM dCa).
Protocol. la(OH) vitamin D3 (Etalpha, Leo Laboratories,
Denmark) was administered i.v. at the end of the dialysis
session. The initial dose was 1 .tg (x3/week) which was
increased stepwise weekly by I g until a total dose between 6
to 9 gIweek was given. iCa, tCa, phosphate and ALP were
assessed weekly. The la(OH) vitamin D3 doses were adapted
according to the predialysis serum iCa levels with the aim of
maintaining pre-dialysis iCa levels of 2.5 to 2.7 mrvi. Intact PTH
and osteocalcin serum levels were assessed monthly. This
study was conducted for four months at the end of the one year
follow-up with varied dCa.
Statistics
The Statistical Analysis System package (S.A.S., 1984, Cary,
North Carolina, USA) was used. Comparison between two or
three groups with several data points each, on a longitudinal
basis, was performed with the analysis of the variance using
Fisher's F value. This applied for intrasession kinetics and
blood pressure studies (3 different groups with 4 data points
each) and long-term assessment of lowering dCa (2 groups with
12 data points) and subsequent treatment with la(OH) vitamin
D3 (2 groups with 4 data points). Longitudinal differences
between two given data points were compared with the Stu-
dent's t-test (normally distributed values) or with Wilcoxon's
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Fig. 1. iCa kinetics during HDFwit/i three different dCa (1.75, 1.5 and 1.25 mM). Arterial (A), venous (B), loss of calcium from dialysate (Di-Do)
(C) and dialysate outlet (D) concentrations are plotted (1.75 mai dCa is plotted as filled triangles and dashed line, 1.5 mat dCa as open squares and
dotted line and 1.25 mat dCa as filled circles and solid line).
test for paired data (not Gaussian distributions). Correlations
between numeric variables were tested with Pearson's r value
and regression analysis was performed when appropriate. The
values are given as mean standard error of the mean and a P
<0.05 is considered to be statistically significant.
Results
Intradialysis studies
Ca and phosphate kinetics. The changes in iCa in the course
of HDF for the three dialysate concentrations are shown in
Figure 1. Arterial iCa concentrations were significantly lower as
the dCa was reduced to 1.5 m and to 1.25 mat (F = 114; P <
0.0001). Sequentially analyzing the modifications in the course
of dialysis, we observed a significant rise in iCa with dCa of 1.75
and 1.5 m (before vs. after comparison by Student's i-test for
paired data: t = 5.77; P < 0.0004 and t = 4.43; P < 0.003,
respectively), while with 1.25 mre dCa, iCa did not change
significantly (t = —1.21; NS). The venous blood and dialysate
outlet followed similar trends. The uptake of Ca from the
dialysate was different with the three dCa (F 55.6; P <
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Fig. 2. iCa kinetics during HD wit/i three different dCa (1.75, 1.5 and 1.25 mM). Arterial (A), venous (B), loss of calcium from dialysate (Di-Do)
(C), and dialysate outlet (D), concentrations are plotted (1.75 mri dCa is plotted as filled triangles and dashed line, 1.5 mss dCa as open squares
and dotted line and 1.25 ms dCa as filled circles and solid line).
0.0001); with 1.25 mt dCa it was small (0.06 0.008 mmollliter)
and altered little during the course of the dialysis, while with
1.75 and 1.5 mi dCa it was higher and tended to decrease (Fig.
1C).
The sieving of iCa [dialysate outlet (Do)Iblood inlet (Bill was
significantly different in HDF when compared to HD alone (F =
6.73; P <0.01); however, this was compensated in HDF by the
infusion of 18 liters containing the same Ca concentration of the
dialysate. Thus, the iCa at the blood inlet did not differ
significantly between HD and HDF (F = 2.59; NS). The
intradialysis kinetics of iCa followed the same trend in HD and
HDF except for the sieving of iCa (Fig. 2).
The serum phosphate levels (blood inlet and outlet) were not
significantly different as the dCa was lowered (F = 1.5; NS)
(Fig. 3). As expected, the reduction in serum phosphate in the
course of dialysis was dependent on the initial serum phosphate
level (Pearson's, r = 0.83;P < 0.0001). However, this reduction
also correlated with HC03 (r = 0.53; P < 0.0001), but the
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2). It can be observed that the dialysis dose given to these
patients is largely greater than that advised by the NCDS study
[10], and it was similar in both groups.
Medications. The treatment with CaCO3 and la(OH) vitamin
D3 are represented in Figure 5. It can be seen that there was a
2.8-fold increase in the amount of CaCO3 taken while the study
progressed after dCa was lowered to 1.25 m. After a one year
follow-up, the dose of CaCO3 administered was 12.6 1 and
6.57 1.9 g/day/patient in the groups treated with 1.25 and 1.5
mM dCa, respectively. At the same time Al(OH)3 was com-
pletely withdrawn in both groups. Oral 1 a(OH) vitamin D3
remained stable during the follow-up period (the extreme values
were 1 and 0.86 p,glweek/patient for the study group and 0.96
and 0.67 pg/week/patient for the control group).
Blood pressure report. None of the patients included in the
low dCa group was receiving antihypertensive drugs. The
24-hour blood pressure records are detailed in Table 3. Systolic
blood pressure was unchanged while decreasing dCa from 1.5
m to 1.25 m. By contrast, diastolic blood pressure and heart
rate decreased significantly when the patients were switched to
1.25 mrvi dCa (Wilcoxon test P < 0.0469 and P < 0.0313,
respectively).
Biochemistry. No significant variations were observed in tCa,
phosphate and ALP (Fig. 6A, B, and C). tCa was stable during
the one year period (F = 0.9; NS) with values which ranged
from 2.38 to 2.53, and was similar in both groups (F = 0.01;
NS). Phosphate was also stable (F = 0.49; NS) and similar in
both groups (F = 2.78; NS), ranging from 1.5 to 1.89 mmol/liter.
Alkaline phosphatases showed opposite trends in the two
groups: while the patients treated with dCa = 1.25 m in-
creased ALP the patients with dCa = 1.5 m decreased their
ALP serum levels. However, Wilcoxon's test for paired data
was not significant for either group. Similarly, the analysis of
the variance did not show statistical differences between the
groups (F = 0.21; NS) or over the time of the study period (F =
0.01; NS).
Concerning iPTH values, although initially similar, they
showed a significant increase in the study group over the year
(Wilcoxon test; P < 0.047), while the control group remained
very stable (Fig. 6D). As a consequence iPTH was statistically
different in both groups (F = 4.76; P < 0.036).
High dose of i.v. la(OH) vitamin D3
High dose i.v. la(OH) vitamin D3 was effective in lowering
iPTH regardless of the dCa. As shown in Figure 7, after four
months of treatment, iPTH clearly decreased in both the group
maintained with dCa = 1.5 and the group switched to dCa =
1.25 m by 75 9 and 72 9%, respectively. The absolute
values were 237 69 pg/liter and 271 150 pg/liter before
starting i.v. 1 a(OH) vitamin D3 therapy for the 1.25 dCa and the
1.5 dCa groups, respectively; at the end of the study iPTH was
72 36 and 73 55 pg/liter, respectively. The levels reached
with the i.v. 1 a(OH) vitamin D3 treatment were similar to those
observed in the same population 16 months before while they
were treated with dCa = 1.5 m. Treatment with i.v. la(OH)
vitamin D3 had to be momentarily stopped because of hyper-
phosphatemia on two occasions in each group.
No differences were observed in osteocalcin levels either
between the groups or after i.v. la(OH) vitamin D3 treatment
(24 3 and 24 5 tg/liter at the start and 24 5 and 28 12
Time, hours
Fig. 3. Intradialytic modifications of serum phosphate level during
HDF. The three different lines correspond to 1.75, 1.5 and 1.25 mM dCa
(1.75 msi dCa is plotted as filled triangles and dashed line, 1.5 msi dCa
as open squares and dotted line and 1.25 msi dCa as filled circles and
solid line).
clinical significance of this is uncertain. A weak but significant
correlation between the serum phosphate level and iCa sieving
(Do/Bi) was observed(r = 0.315; P <0.0001). However, it must
be pointed out that although the phosphate levels did not alter
significantly in the course of the study, the amount of phosphate
binders taken by the patients increased (see below), and thus
definite conclusions regarding the interrelationship of the serum
phosphate and the dCa are difficult to draw.
Blood pressure and dialysis tolerance. Figure 4 shows intra-
dialytic changes in systolic and diastolic blood pressure as well
as heart rate during HDF with the three different dCa. A
decrease in both SBP and DBP during the session was observed
which was reversed with fluid restitution at the end of the
dialysis. The heart rate decreased after the start of the session
and started to increase from the second hour to compensate for
the weight loss. The same patterns were observed with the
three different dCa concentrations. DBP significantly decreased
when lowering dCa to 1.25 mrvi (F = 4.6; P < 0.01). In contrast,
decreasing dCa had no effect on SBP (F = 2.5; NS).
The intradialytic events most frequently recorded were hy-
potension, cramps and headache. As it can be seen in Table 1,
the average occurrence of intradialytic events was very low: 10
hypotensive episodes, 2.2 cramps and 1.7 headaches per 100
dialysis sessions, respectively. Although headaches disap-
peared with dCa = 1.25 m, because of the very low occur-
rence, the clinical relevance of these variations is not clear.
Long-term effects of using 1.25 m dCa
Dialysis dose. The dialysis characteristics and delivered dose
as measured by urea kinetic modeling were stable throughout
the follow-up period in both the study and control group (Table
E
a)
in
ca
pg/liter, respectively, in the
months).
The evolution of tCa, phosphate and ALP is presented in
Table 4. There was a significant increase in tCa in the dCa
1.25 group (P < 0.05). The ALP tended to increase in both
groups (17.3% and 10% in dCa 1.25 and dCa = 1.5 mM
groups, respectively); however, this increase was not signifi-
cant.
Discussion
From the studies by Slatopoisky and co-workers it has been
known that control of the serum phosphate level is of great
importance in the treatment and prevention of hyperparathy-
study and control groups after 4
E
E
a.
Table 1. Intradialysis morbidity during 117 HDF sessions
dCamM 1.75 1.5 1.25
Hypotensive episodes 13 (11) 7 (6) 15 (12.8)
Cramps 3 (2.6) 1 (0.8) 4 (3.4)
Headache 4 (3.4) 2 (1.7) 0
The values given are the absolute number of events and in brackets
events per 100 dialysis sessions.
roidism [11]. Recently, new phosphate intestinal binders have
been proposed to replace Al(OH)3 because of the latter's
well-recognized toxicity [12, 13]. Although Ca acetate may be
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mM dCa as filled circles and solid line).
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Table 2. Dialysis characteristics and dose during the one year follow-
up of the study in both groups (control group dialyzed with 1.5 mM
dCa and study group dialyzed with 1.25 mi dCa)
Month 0 4 8 12
Study group
dCa mmol/liter 1.5 1.25 1.25 1.25
QB mI/mm 356 10 367 8 375 10 359 8
REC % 14.7 2 13 1 12.8 1 13 3
Kr/V 1.46 0.07 1.48 0.06 1.44 0.1 1.51 0.1
Control group
dCa mmol/liter 1.5 1,5 1.5 1.5
QB mi/mm 377 11 367 4 369 7 380 8
REC % 17.5 3 13.5 2 16.3 4 14.6 4
Kr/V 1.57 0.07 1.48 0.07 1.5 0.1 1.44 0.06
more efficient [3, 14], CaCO3 remains the most commonly used
binder, particularly in France where Ca acetate is not available,
However, the use of CaCO3 is limited by the induction of
hypercalcemia in patients. To avoid the occurrence of hyper-
calcemia, the use of a low Ca dialysate has been proposed,
particularly for patients with high serum Ca levels and yet
uncontrolled phosphate [6, 15—17]. Such an approach has also
been previously reported as successful in treating acute malig-
nant hypercalcemia and hypertension [18]. However, concern-
ing the intradialysis Ca kinetics and balance, a single study has
been recently reported by Hou et al [19] assessing tCa balance
from the dialysate in HD with low dCa [19].
With the technical progress achieved in the hemodialysis
field, new dialysis membranes and techniques have become
more commonly used [20]. We have recently reported the
results of hemodiafiltration treatment on cardiovascular param-
eters and the clearances of small and large molecules [21].
However, no previous studies assessing the intrasession iCa
kinetics in HD and the possible differences in HDF have been
reported. Similarly, the long-term effects of lowering dCa have
not been studied in HDF. In the present study, we assessed the
intrasession kinetics for iCa and phosphate both during HD and
HDF in the same patients, using three different dCa concentra-
tions. We also studied the long-term effects of low dCa (1.25
mM) on blood pressure and hyperparathyroidism, and observed
an increase in intact PTH levels which was not present in a
group of patients maintained with 1.5 m dCa. We then treated
the patients with high dose of i.v. la(OH) vitamin D3 and
obtained an equally satisfactory correction of the iPTH levels in
both groups of patients.
Concerning the study of the intradialytic Ca kinetics, we
observed a clear increase in iCa during the sessions using 1.75
mM dCa which was still significant with 1.5 msi dCa. These
intradialytic positive Ca variations were not observed with 1.25
mM dCa. These findings are consistent with the dialysate
collection studies reported by Hou et al [19]. Comparing the
kinetics in HD and HDF, we observed a significantly higher
sieving for iCa in HDF which shows that Ca transfers through
the dialyzer are different in HD and HDF. In HDF between 15
and 20 liters of plasma water are filtered during the treatment.
This convective component results in an increased clearance
which is more prominent for high molecular weight compounds
but is also observed in small molecules [21]. Thus, the added
convection results in an increased Ca loss which is compen-
sated by the infusion of equal amounts of ultrafiltered dialysate
(containing the same Ca concentration as the dialysate). As a
consequence the iCa in the blood taken from the blood inlet was
similar in HDF versus HD. Confirming this, Malberti and
Surian [22] observed a significant decrease in Ca when perform-
ing HDF with Ca free infusate. Goldsmith et al in 1974 [23]
studied the Ca flux during hemodialysis and showed that there
is a significant correlation between serum phosphate levels and
Ca transfer from the dialysate to the blood. Although in our
study we found this correlation as well, its r value was relatively
small (0.31).
It is known that iCa is a determinant of the blood pressure
[24, 25]. It is positively inotropic [26] and also controls arterial
smooth muscle contraction, modulating peripheral vascular
resistances [27]. It has been previously shown that increasing
iCa serum levels during dialysis result in an increase in mean
arterial pressure [28]. However, while small blood pressure
modifications during dialysis are statistically significant, they
are frequently clinically irrelevant [29]. In our study, decreasing
dCa to 1.25 m induced a minor but statistically significant
decrease in diastolic blood pressure but no modifications of the
systolic blood pressure. It has been demonstrated that the iCa
actions to increase cardiac output and to increase systemic
vascular resistance are distinguishable by the range of the iCa
level. While an increase from low iCa to normal induces
predominantly cardiac modifications, a further increase from
normal to high iCa results in an increase in systemic vascular
resistances [30]. These results are in keeping with our data since
none of the patients included in this study was hypocalcemic
and we found a significant decrease in DBP and no modification
on SBP. These modifications did not translate into an impaired
cardiovascular tolerance and the ultrafiltration rate was able to
be maintained at the same level with no increase in body
weight.
It is interesting to note that the modifications in blood
pressure observed intradialytically were also found in the
long-term study by monitoring the blood pressure for 24 hours.
Again the mean of the one day record showed a significant
difference in DBP and heart rate, but not in SBP. Although it is
always satisfying to control DBP, whether this minor drop in
blood pressure is relevant for the patient in the long-term
remains to be demonstrated.
Previous reports have analyzed the benefits of using the low
dCa in association with CaCO3 to control serum phosphate
levels and avoid hypercalcemia [6, 15, 16]. Mactier et al [15] and
Sawyer et al [16] modified dCa from patient to patient according
to serum Ca levels with a dCa ranging from 1.75 to 1.05 m, and
analyzed the modifications after four months of using CaCO3.
While Sawyer et al [16] found a significant decrease in intact
PTH, Mactier et al [15] found a 22% increase in C-terminal PTH
which did not reach statistical significance. In the study by
Slatopolsky et al [6] the dCa was maintained constant at 1.25
m for seven months and iPTH decreased by 20%, but again
the variation was not significant. The CaCO3 dose taken by our
patients was higher than those used in these reports. However,
despite obtaining a stable serum total Ca which was similar in
both the 1.5 and 1.25 mM dCa group, iPTH increased signifi-
cantly during the phase of 1.25 mM dCa treatment. This
increase in iPTH was specific for the 1.25 dCa group, as it was
not observed in the control group (dCa = 1.5), and appeared
Co
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Fig. 5. Calcium carbonate and oral la(OH) vitamin D3 treatments during one year follow-up. Open bars correspond to the control group
maintained with dCa = 1.5 m for 1 year, filled bars correspond to the study group (switched to dCa = 1.25 mM). Values are given as mean
SEM and the units are g/day/patient and jgIweekIpatient for CaCO3 and oral la(OH) vitamin D3, respectively.
Table 3. Twenty-four hour blood pressure record of the patients
under study performed twice: During dCa = 1.5 mi
and dCa = 1.25 mM
dCa SBP DBP Heart rate
1.5 mM 133 5.8 80.6 3 89.4 4
1.25 mi 126 5.3 75.2 3 85.3 3
The means for the total values recorded per patient were calculated
and taken as single value. The mean standard error of the mean of
these values is given for the population's analysis, and Wilcoxon's test
for paired data was applied to assess the differences. ap < 0.05
despite the stable Ca, phosphate and ALP serum levels. An
acute decrease in iPTH levels has been reported during HD
with 1.75 m dCa [311, and these authors have proposed this
effect as a test to assess the ability to down-regulate the
parathyroid gland. Other authors have confirmed this intradia-
lytic decrease in PTH when a positive iCa balance is produced,
and have shown that PTH inhibition is temporary as the
predialysis level of PTH before the next treatment is unchanged
[32, 33]. Although unlikely because the iPTH decrease is not
protracted, it could be that the absence of such a periodic
inhibition participated in the increase in iPTH we observed after
one year treatment with 1.25 mM dCa.
There is increasing evidence showing that pulse therapy with
vitamin D3 derivatives suppresses secondary hyperparathyroid-
ism in dialysis patients [34]. The 1 ,25(OH)2 vitamin D3 form is
the derivative most commonly reported. It has been used in oral
[35] and i.v. therapy both in hemodialysis [34, 36] and perito-
neal dialysis patients [371. Alternatively, 24,25(OH)2 vitamin D3
[38] and 1 a(OH) vitamin D3 [391 have also been proposed. For
la(OH) vitamin D3, the first reports demonstrated good efficacy
in decreasing iPTH [40, 41]; however, these authors reported an
increase in serum Ca which was a limiting factor for the
treatment, as they used dCa ranging from 1.5 to 1.8 mM.
Recently, Mornière et al [42] used i.v. la(OH) vitamin D3 in
patients dialyzed with a dCa = 1.62 m, after discontinuing
CaCO3. In this report the serum phosphate control with
Mg(OH)2 was rather unsatisfactory forcing a decrease in
1 a(OH) vitamin D3 doses and subsequent hyperparathyroidism
relapse [42]. Since the patients included in our study were
treated with lower dCa, we used i.v. la(OH) vitamin D3 without
discontinuing CaCO3. To assess the effect of the dCa on the
treatment with 1 a(OH) vitamin D3, we administered the same
treatment in a control group dialyzed with 1.5 mri dCa. In both
groups of patients i.v. la(OH) vitamin D3 was similarly effec-
tive in decreasing iPTH and the decrease (—70%) was equiva-
lent to those previously reported [40, 41]. Serum Ca levels
increased after i.v. la(OH) vitamin D3 treatment; however,
they remained within an acceptable range. 1 a(OH) vitamin D3
i.v. therapy had to be momentarily discontinued only on two
occasions in each group. This confirms that when the patients
are treated with dCa of 1.5 mmM or lower, and have a
satisfactory phosphate and Ca levels, high doses of i.v. la(OH)
vitamin D3 can be safely used with no need for discontinuing
CaCO3.
In summary, the present study shows that low Ca dialysate
can be used both in HD and HDF with no deleterious intradi-
alytic events and no associated hypotensive episodes, provided
that the infusion fluid in HDF is not Ca free. An increased Ca
oral intake to control serum phosphate levels is allowed without
inducing hypercalcemia since the positive intradialytic balance
is avoided. Lowering dCa to 1.25 m results in a minor but
statistically significant decrease in DBP which may be of some
benefit for the patient in the long-term. However, despite an
increased oral Ca intake and satisfactory serum phosphate
control an increase in serum iPTH was observed with 1.25 mM
dCa. High doses of i.v. la(OH) vitamin D3 were effective in
reversing the iPTH increase. This latter treatment could be
equally used in both groups, patients treated with 1.5 and 1.25
mM dCa.
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Table 4. Evolution of tCa, phosphate, and ALP after i.v. la(OH) vitamin D3
Before 1 Month 2 Months 3 Months 4 Months
dCa = 1.25mM
tCa 2.42 0.05 2.51 0.07 2.72 0.08 2.66 0.06 2.78 0.05
Phos 1.75 0.04 1.69 0.1 1.77 0.09 2.04 0.2 1.67 0.09
ALP 62.8 7.8 63 7.5 58.7 7.1 57 8 52.5 6.3
dCa = 1.5 mM
tCa 2.78 0.05 2.52 0.07 2.63 0.05 2.61 0.08 2.72 0.05
Phos 1.64 0.1 1.41 0.12 1.66 0.11 1.8 0.08 1.74 0.2
ALP 59.8 5.3 64.5 9 64.8 7.9 61 7.9 54 7.9
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